Eagle Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eagle Pharmaceuticals, Inc.
The Israeli firm’s third-quarter revenues and profits decreased as its product sales dipped due to alternative options and generic competition leading it to lower its full-year guidance, but its opioid crisis financial settlement remains on track.
With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.
Arcutis's CEO believes that with "a modest investment," the company can generate proof-of-concept data "against a de-risked target in a high-value indication,” Ducentis's preclinical atopic dermatits drug DS-234.
Lack of scale, the need for further funding and problems getting reimbursement for its adrenal insufficiency products left the Wales-headquartered firm vulnerable to a takeover and San Diego's Neurocrine has swooped.
- Generic Drugs
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- Arsia Therapeutics
- Eagle Biologics